3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
11
Prostatic Neoplasms
9
Uterine Neoplasms
2
Hyperthermia
2
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Locally Advanced Cervical Adenocarcinoma
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Clear Cell Adenocarcinoma
1
Directly Observed Therapy
1
Cervical Adenocarcinoma
1
Carcinoma, Renal Cell
1
Adenocarcinoma
1
Interventions
Cisplatin
20
Radiotherapy
16
Paclitaxel
14
Carboplatin
12
pembrolizumab
11
Drug Therapy
11
tislelizumab
10
Fluorouracil
8
Neoadjuvant Therapy
7
130-nm albumin-bound paclitaxel
7
sintilimab
5
Esophagectomy
5
toripalimab
4
Tegafur
4
TP protocol
4
Nivolumab
4
Irinotecan
4
Immunotherapy
4
spartalizumab
3
S 1 (combination)
3
Oxaliplatin
3
Leucovorin
3
Itraconazole
3
Docetaxel
3
Albumin-Bound Paclitaxel
3
nimotuzumab
2
apatinib
2
Taxes
2
Radiotherapy, Intensity-Modulated
2
Immune Checkpoint Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Squamous Cell Carcinoma
×
Brachytherapy
×
Clear all
NCT07152678
2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2
Recruiting
60 enrolled